BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BC Week In Review | Dec 30, 2016
Company News

OSE Immunotherapeutics, Servier deal

OSE Immunotherapeutics granted Servier an option to license exclusive, worldwide rights to develop and commercialize Effi-7 . The humanized mAb targeting IL-7 receptor ( CD127 ) is in preclinical testing to treat ulcerative colitis (UC). OSE will continue...
BC Innovations | Jul 26, 2012
Cover Story

Taming T cells in T1D

Separate teams at the University of California, San Francisco and Pfizer Inc. have evidence that blocking Il-7 signaling in mice can arrest the autoimmune activity behind type 1 diabetes. 1,2 Whether the findings will translate...
BC Innovations | Jul 26, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes IL-7 receptor (IL-7R; CD127) Two studies in mice suggest antagonizing CD127 could help treat type 1 diabetes. In a mouse model of type...
Items per page:
1 - 4 of 4